AbbVie Reports Phase 3 U-EXCEED Results for Rinvoq in Crohn's Disease

AbbVie today announced results from the Phase 3 U-EXCEED trial evaluating Rinvoq (upadacitinib) in patients with moderately to severely active Crohn's disease who had an inadequate response or intolerance to biologic therapy. The trial met its primary endpoint, demonstrating a significantly higher rate of clinical remission compared to placebo at week 12.